WO2023220281A1 - Compositions et méthodes de traitement et de prévention d'une coinfection avec eimeria et clostridium - Google Patents

Compositions et méthodes de traitement et de prévention d'une coinfection avec eimeria et clostridium Download PDF

Info

Publication number
WO2023220281A1
WO2023220281A1 PCT/US2023/021898 US2023021898W WO2023220281A1 WO 2023220281 A1 WO2023220281 A1 WO 2023220281A1 US 2023021898 W US2023021898 W US 2023021898W WO 2023220281 A1 WO2023220281 A1 WO 2023220281A1
Authority
WO
WIPO (PCT)
Prior art keywords
feed additive
poultry
additive composition
eimeria
feed
Prior art date
Application number
PCT/US2023/021898
Other languages
English (en)
Inventor
Andrea Marie BINNEBOSE
Gretel GOMEZ-JIMENEZ
Victor Leonard Joseph NSEREKO WANTATE
Kevin Townsend WATTS
Adam T. ZARTH
Original Assignee
Can Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Technologies, Inc. filed Critical Can Technologies, Inc.
Publication of WO2023220281A1 publication Critical patent/WO2023220281A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/90—Protozoa ; Processes using protozoa

Definitions

  • Coccidiosis and necrotic enteritis are infections of the intestines of domesticated animals that often occur simultaneously.
  • Coccidiosis infection is caused by various pathogenic strains of protozoa including those of the genus Eimeria and necrotic enteritis is caused by pathogenic strains of Clostridia bacteria.
  • the bacteria and protozoa are consumed inadvertently into the digestive tract of an animal as oocysts when foraging. Once inside the animal, the sporulated oocysts release sporocysts which proceed through the life cycle of the organism and release the initial infective stage sporozoites.
  • the sporozoites invade the mucosal membranes of the jejunum, ileum, and caecum, where they reproduce un-sporulate oocytes. Their reproductive life cycle can cause mucosal tissue problems, such as imbalances in absorption of both water and electrolytes, and can lead to lesions throughout the intestines, resulting in diarrhea. During the infection, the new population of un-sporulated oocysts are released back into the environment via the animal’s feces.
  • Necrotic enteritis can be caused by Clostridia bacteria also consumed inadvertently by consumed by animals during foraging.
  • Clostridia bacteria are a class of gram-positive, sporeforming, anaerobic bacteria that are present in the soil, vegetation, and as part of the normal flora in the gastrointestinal tract of animals.
  • Pathogenic species of Clostridium are known for producing several detrimental toxins and can be found throughout the gastrointestinal tract of animals resulting in several enteric diseases.
  • Poultry that have prior mucosal damage in the intestine, such as that caused by a coccidiosis infection, can be particularly susceptible to further infection with the opportunistic pathogenic strain of Clostridia, Clostridium perfringens.
  • the present disclosure provides a feed additive composition including a microbial fermentate product, where the microbial fermentate product is present in the feed additive composition in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa in an animal.
  • the Clostridium bacteria can include Clostridium perfringens,' and the Eimeria protozoa can include one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella.
  • the inhibitory effect can include a direct or indirect inhibition of growth of Clostridium bacteria and a direct or indirect inhibition of the reproduction or shedding of Eimeria protozoa.
  • the inhibitory effect against Clostridium bacteria and Eimeria protozoa can result in one or more beneficial effects for the animal, where the one or more beneficial effects include improved health measures or enhanced performance measures, or a combination thereof.
  • the improved health measures can include reducing one or more of ceca lesion number, ceca lesion severity, liver lesion number, or liver lesion severity.
  • the enhanced performance measures can include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination thereof.
  • the microbial fermentate product is a bacterial fermentate or a fungal fermentate. In an aspect, the microbial fermentate product is a postbiotic product.
  • the microbial fermentate product can include a bacterial or a fungal fermentate of Acetobacter pasteurianus, Acetobacter peroxydans, Acetobacter okinawensis, Acidipropionibacterium acidipropionici, Arxula adeninivorans, Bacillus altitudinis, Bacillus atrophaeus, Bacillus aryabhattai, Bacillus cereus, Bacillus coagulans, Bacillus halotolerans, Bacillus megaterium, Bacillus pumilis, Bacillus safensis.
  • Bacillus subtilis Bacillus velezensis, Bacillus xiamenensis, Brevibacillus laterosporus, Candida carpophila, Candida fermentati,, Debaryomyces hansenii, Enterococcus mundtii, Kazachstania martiniae, Lactobacillus brevis, Lactobacillus paracasei, Lactobacillus pentosus, Lactobacillus pentosus plantarum, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactococcus lactis, Leuconostoc citreum, Mucor indicus, Paenibacillus taichonnesis, Pediococcus acidilactici, Pediococcus pentosaceus, Phaffla rhodozyma, Pichia barkeri, Priceomyces metis sophilus, Rhodotorula graminis, Rhodospori
  • the microbial fermentate product can include a bacterial fermentate of Bacillus megaterium, Lactobacillus lactis, Priceomyces melissophilus, Schwanniomyces vanrijiae, Saccharomyces cerevisiae, or Weissella confusa, or any combination thereof.
  • the feed additive compositions herein can include a solid or a liquid.
  • the feed additive compositions herein can include a solid composition in the form of granules, flakes, pellets, powders, tablets, capsules, cubes, crumbles, pastes, gels, or any combination thereof.
  • the feed additive composition can include a liquid spray, a liquid water additive, a liquid drench, or a liquid water dip for application.
  • the feed additive compositions herein contain an amount of microbial fermentate product effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa at an inclusion rate falling within a range from 0.01 kg/tonne to 15.0 kg/tonne.
  • the feed additive compositions herein can be a component of a poultry feed product.
  • the feed additive composition or poultry feed product can be formulated for a chicken or a turkey.
  • the microbial fermentate products of the feed additive compositions herein can include one or more molecular components including hpopeptides, polar lipids, isoprenoid-containing species, or combination thereof.
  • the microbial fermentate product can include one or more of lipopeptide NO; gageostatin C; surfactin; neocopiamycin A; [Ile7] -surfactin; fengycin C; SNA-60-367-4; SNA-60-367-9; SNA-60-367-13; N-(3-oxodecanoyl)-L-homoserine lactone; serinolamide C; N-stearoylalanine; L-755807; aspochalasin J; (4E,6Z)-N-(5-ethyl-5-methyl-2-oxofuran-3-yl)-8-(3-heptyloxiran-2-yl)-3- hydroxyocta-4
  • the present disclosure provides a method for feeding poultry the feed additive compositions described herein.
  • the method can include feeding a chicken or a turkey the feed additive compositions described herein.
  • the present disclosure provides a method for inhibiting the growth of Clostridium bacteria and reproduction or shedding of Eimeria protozoa in poultry.
  • the method can include administering a feed additive composition including a microbial fermentate product to the poultry.
  • the microbial fermentate product can be present in the feed additive composition in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa.
  • the Clostridium bacteria can include one or more of Clostridium baratii, Clostridium botulinum, Clostridium colinum, Clostridium difficile, Clostridium fallax, Clostridium perfringens, and Clostridium septicum.
  • the Eimeria protozoa can include one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella.
  • the inhibitory' effect can include a direct or indirect inhibition of the growth of Clostridium bacteria and a direct or indirect inhibition of reproduction or shedding of Eimeria protozoa.
  • the inhibitory' effect against Clostridium bacteria and reproduction or shedding of Eimeria protozoa can result in one or more beneficial effects for the poultry.
  • the one or more beneficial effects can include improved health measures or enhanced performance measures, or a combination thereof.
  • the improved health measures can include reducing one or more of ceca lesion number, ceca lesion severity, liver lesion number, or liver lesion severity.
  • the enhanced performance measures can include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination thereof.
  • producing the inhibitory effect in poultry fed the feed additive composition is observed relative to poultry fed a diet lacking the feed additive composition.
  • the method further can include administering the feed additive composition as a daily feed ration that is fed to the poultry on most days or on all days.
  • the method further can include that the amount of microbial fermentate product effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa includes an inclusion rate falling within a range from 0.01 kg/tonne to 15.0 kg/tonne.
  • administering a feed additive composition including a microbial fermentate product includes a feed additive composition including a bacterial fermentate of Acetobacter pasteurianus, Acetobacter peroxydans, Acetobacter okinawensis, Acidipropionibacterium acidipropionici, Arxula adeninivorans, Bacillus altitudinis, Bacillus atrophaeus, Bacillus aryabhattai, Bacillus cereus, Bacillus coagulans, Bacillus halotolerans, Bacillus megaterium, Bacillus pumilis, Bacillus safensis, Bacillus subtilis, Bacillus velezensis, Bacillus xiamenensis, Brevibacillus laterosporus , Candida carpophila, Candida fermentati, Debaryomyces hansenii, Enterococcus mundtii, Kazachstania martiniae, Lactobacillus bre
  • a method for reducing or preventing a coccidiosis and necrotic enteritis coinfection in poultry including administering a feed additive composition including a microbial fermentate product to the poultry, where the microbial fermentate product is present in the feed additive composition in an amount effective to produce an inhibitory effect against Clostridium perfringens and Eimeria protozoa.
  • the Eimeria protozoa include one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella.
  • the inhibitory effect can result in one or more beneficial effects for the poultry.
  • the inhibitory effect can include a direct or indirect inhibition of the growth of Clostridium bacteria and a direct or indirect inhibition of reproduction or shedding of Eimeria protozoa.
  • the one or more beneficial effects can include improved health measures or enhanced performance measures, or a combination thereof.
  • the improved health measures can include reducing one or more of ceca lesion number, ceca lesion severity, liver lesion number, or liver lesion severity.
  • the enhanced performance measures can include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination thereof.
  • the method further can include challenging the poultry with Clostridium perfringens at a concentration of from 1.0 x 10° to 1.0 x 10 10 CFU and Eimeria protozoa from 1.0 * 10° to 1.0 * 10 10 sporulated oocysts or sporozoites in a daily ration of poultry feed per poultry.
  • the method further can include where the poultry have acquired an infection with Clostridium perfringens and Eimeria protozoa in their habitat in an amount effective to cause disease in the poultry.
  • the present disclosure provides a method for enhancing performance measures in poultry.
  • the method can include administering a feed additive composition including a microbial fermentate product to poultry, where the microbial fermentate product is present in the feed additive composition in an amount effective for enhancing performance measures in the poultry.
  • the method includes enhancing performance measures in poultry that are coinfected with Clostridium perfringens and one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella.
  • the enhanced performance measures can include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination thereof.
  • the increase in weight can include an average weight increase of from 0.5% to 30% in a population of poultry fed the feed additive composition as compared to an average weight in a population of poultry fed a diet lacking the feed additive composition.
  • the decrease in feed conversion ratio can include an average decrease of from 0.5% to 10% in the feed conversion ratio of a population of poultry fed the feed additive composition as compared to an average feed conversion ratio in a population of poultry fed a diet lacking the feed additive composition.
  • the increase in egg production can include an average increase of from 0.5% to 25% in the egg production of a population of poultry fed the feed additive composition as compared to a population of poultry fed a diet lacking the feed additive composition.
  • the decrease in mortality can include an average decrease of from 0.5% to 40% in the mortality' of a population of poultry fed the feed additive composition as compared to a population of poultry fed a diet lacking the feed additive composition.
  • the decrease in morbidity can include an average decrease of from 0.5% to 40% in the morbidity of a population of poultry fed the feed additive composition as compared to a population of poultry fed a diet lacking the feed additive composition.
  • feed additive compositions and methods for feeding poultry are included to prevent or reduce coinfection with Clostridium bacteria and Eimeria protozoa in poultry, as well as to improve various health measures and to enhance performance measures in the animals.
  • the present disclosure provides feed additive compositions that can include a microbial fermentate product in an amount effective to produce an inhibitory effect against coinfection with Clostridium bactena and Eimeria protozoa in an animal.
  • the coinfection with Clostridium bacteria and Eimeria protozoa can include an infection in the animal that can be a clinical infection or a subclinical infection.
  • the coinfection with Clostridium bacteria and Eimeria protozoa can be naturally acquired in an animal’s habitat in an amount effective to cause disease in the animal, or the coinfection with Clostridium bacteria and Eimeria protozoa can be acquired by challenging an animal in a controlled setting.
  • the present disclosure provides the feed additive compositions in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa by reducing or preventing a coinfection with Clostridium bacteria and Eimeria protozoa through Clostridium growth inhibition and inhibition of Eimeria reproduction or shedding.
  • the effective amount of feed additive composition in the diet can directly or indirectly inhibit the growth of Clostridium bacteria and the reproduction or shedding of Eimeria protozoa and can confer one or more beneficial effects to the animal(s).
  • a “beneficial effect” can refer to one or more improved health measures or one or more enhanced performance measures in an animal or group of animals.
  • Various improved health measures can include a reduction in one or more of ceca lesion number, ceca lesion severity, liver lesion number, or liver lesion severity.
  • Various enhanced performance measures can include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination thereof.
  • the beneficial effects observed herein can be a direct or indirect result of the inhibition of the growth of Clostridium bacteria and can be a direct or indirect result of the reproduction or shedding of Eimeria protozoa. Both improved health measures and enhanced performance measures are described in more detail elsewhere herein.
  • microbial fermentate product can refer to a composition containing one or more of non-viable microorganism(s), spores produced by fermentation of said microorganism(s) prior to inactivation, and metabolites produced by fermentation of said microorganism(s) prior to inactivation.
  • a microorganism can be subject to a fermentation process to form a fermentate which, after inactivation, includes non-viable microorganisms, spores, cell fractions, and metabolites (e.g., fatty acids, polysaccharides, phenols, peptides, proteins, vitamins, amino acids, and the like) obtained from the fermentation process.
  • Various spore-forming microorganisms suitable for generating the microbial fermentate products herein can generate spores during fermentation. Spores generated during fermentation can remain a component of the microbial fermentate product, or they can be removed from the microbial fermentate product.
  • Various non-spore forming microorganisms suitable for generating the microbial fermentate products herein do not generate spores, and any fermentates produced by non-spore forming microorganisms can be referred to further herein as a “postbiotic product.”
  • the microbial fermentate product herein can be a bacterial fermentate or a fungal fermentate, where the fungal fermentate further can include a yeast fermentate.
  • microorganisms suitable for generating the microbial fermentate products herein include, but are not limited to, Acetobacter pasteurianus, Acetobacter peroxydems, Acetobacter okinawensis, Acidipropionibacterium acidipropionici, Arxula adeninivorans, Bacillus altitudinis, Bacillus atrophaeus, Bacillus aryabhattai, Bacillus cercus, Bacillus coagulans, Bacillus halotolerans, Bacillus megaterium, Bacillus pumilis, Bacillus safensis, Bacillus subtilis, Bacillus velezensis, Bacillus xiamenensis, Brevibacillus laterosporus, Candida carpophila, Candida fermentati, Debaryomyces hansenii, Enterococcus mundtii, Kazachstania martiniae, Lactobacillus brevis, Lactobacillus
  • the suitable bacteria can include Bacillus velezensis, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactococcus lactis, Pediococcus pentosaceus, Priceomyces melissophilus, and Schwanniomyces vanrijiae, alone or in any combination thereof.
  • the microbial fermentate products are suitable for use in the methods described elsewhere herein
  • the feed additive compositions herein can include a microbial fermentate product or they can include a microbial fermentate product plus other components as described below.
  • the feed additive compositions can include a microbial fermentate product in the feed additive composition in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa in poultry.
  • the inhibitory effect against Clostridium bacteria and Eimeria protozoa can result in one or more beneficial effects for the animals feed the feed additive compositions, as will be discussed in more detail below.
  • the feed additive compositions can be fed directly to poultry or they can be fed to poultry as a component of a poultry feed.
  • the feed additive compositions can be in any suitable form, including a solid or a liquid.
  • the feed additive composition can be a solid composition in the form of granules, flakes, pellets, powders, tablets, capsules, cubes, crumbles, pastes, gels, and the like.
  • the feed additive composition can be a dry solid.
  • the feed additive composition can be a liquid spray, a liquid water additive, or a liquid water dip bath for application to a feed product.
  • the food additive compositions herein can include a liquid drench.
  • the liquid drench can include one or more of a suspension, a solution, or an emulsion.
  • the feed additive compositions herein can include a mixture of a solid and liquid component.
  • the feed additive composition can be suitable for administration in the diet of various species of poultry as described in more detail below.
  • the feed additive compositions herein can have both shelf-life stability and temperature stability.
  • the feed additive compositions herein further can be stable during processing and storage.
  • the feed additive compositions can have a shelf life of approximately 24 months.
  • the feed additive compositions can have a shelf life of up to approximately 30 months.
  • the feed additive compositions can be stable at any storage temperature from 18 °C to 45 °C.
  • the feed additive compositions herein further can be stable at various additional storage temperatures ranging from -80 °C to 18 °C.
  • the feed additive compositions herein further can be stable at processing temperatures that meet or exceed 90 °C during processing, such as during pelleting, extrusion, and the tike.
  • the amount of feed additive composition administered in the diet of an animal can vary depending on the stage of animal growth and the nutritional requirements of the animal.
  • the amount of feed additive composition can be determined based on the concentration of microbial fermentate product required to provide an amount effective to produce an inhibitory effect against Clostridium bacteria.
  • the inhibitory effect can be a direct or indirect inhibition of the growth of Clostridium bacteria.
  • the microbial fermentate products herein can reduce or prevent an infection in an animal against various species of Clostridium bacteria, including, but not to be limited to Clostridium baratii, Clostridium botulinum, Clostridium colinum, Clostridium difficile, Clostridium fallax, Clostridium perfringens, and Clostridium septicum.
  • the amount of feed additive composition used herein can be determined based on the concentration of microbial fermentate product required to provide an amount effective to inhibit the growth of Clostridium perfringens.
  • the microbial fermentate products herein can be used in an amount effective to inhibit the growth of Clostridium perfringens types A, B, C, D, E, and/or G.
  • the microbial fermentate products herein can be used in an amount effective to inhibit the growth of Clostridium perfringens type A/G.
  • the amount of feed additive composition further can be determined based on the concentration of microbial fermentate product also required to provide an amount effective to produce an inhibitory effect against Eimeria protozoa.
  • the inhibitory effect can be a direct or indirect inhibition of the reproduction or shedding, or both, of Eimeria protozoa.
  • the microbial fermentate products herein can reduce or prevent an infection in an animal against various species of Eimeria protozoa, including, but not to be limited to Eimeria acervulina, Eimeria brunetti, Eimeria hagani, Eimeria maxima, Eimeria mitis, Eimeria mivati, Eimeria necatrix, Eimeria praecox, or Eimeria tenella.
  • the amount of feed additive composition used herein can be determined based on the concentration of microbial fermentate product required to provide an amount effective to inhibit the reproduction or shedding, or both, of Eimeria protozoa.
  • the microbial fermentate products herein can be used in an amount effective to inhibit reproduction or shedding, or both, of one or more Eimeria protozoa species.
  • the feed additive compositions herein can include a microbial fermentate product that is sorbed by a carrier and fed to an animal.
  • the microbial fermentate products can be absorbed by a carrier material, adsorbed by a carrier material, or both.
  • Suitable earners for use herein can include, but are not limited to, soy hulls, wheat hulls, or combinations thereof.
  • the carrier can include an inert insoluble fiber carrier such as a cellulose powder, hemicellulose, lignin, or combinations thereof.
  • the carrier can include a mineral such as a calcium carbonate.
  • the microbial fermentate products herein can be sorbed by the carriers, including absorbed or adsorbed, in any ratio suitable to transport the effective amount to the ceca of poultry.
  • the feed additive compositions herein can be added as a component of a poultry feed and then fed to an animal.
  • the microbial fennentate product herein can be added to the diet of poultry in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa.
  • the microbial fermentate product can be present at an amount effective at a concentration of from 0.01 kg/tonne, 0.05 kg/tonne, 0.10 kg/tonne, 0.15 kg/tonne, 0.20 kg/tonne, 0.25 kg/tonne, 0.30 kg/tonne, 0.35 kg/tonne, 0.40 kg/tonne, 0.45 kg/tonne, 0.50 kg/tonne, 0.55 kg/tonne, 0.60 kg/tonne, 0.65 kg/tonne, 0.70 kg/tonne, 0.75 kg/tonne, 0.80 kg/tonne, 0.85 kg/tonne, 0.90 kg/tonne, 0.95 kg/tonne, 1.0 kg/tonne, 1.25 kg/tonne, 1.5 kg/tonne, 1.75 kg/tonne, 2.0 kg/tonne, 2.25 kg/tonne, 2.5 kg
  • the microbial fermentate product can be added to the diet of an animal at an inclusion rate that can include more than 15.0 kg/tonne microbial fermentate if such an inclusion rate does not preclude the animal from being supplied the nutritional requirements necessary to promote and maintain the normal growth and health of the animal.
  • inclusion rate can include more than 15.0 kg/tonne microbial fermentate if such an inclusion rate does not preclude the animal from being supplied the nutritional requirements necessary to promote and maintain the normal growth and health of the animal.
  • the feed additive compositions herein can be administered directly to any suitable poultry species or can be administered to poultry as a component of a poultry feed.
  • the poultry feed suitable for use herein can be a complete poultry feed to which the feed additive composition is added.
  • a complete poultry feed can include a nutritionally adequate feed for poultry that is compounded to be fed as the sole ration and can maintain life and/or promote growth and production without any additional substances being consumed except water.
  • Complete poultry feeds can be compounded mixtures containing any combination of nutrients, as described below, plus various energy sources such as grains, fat, and protein.
  • various major vitamins and minerals can be added to the complete poultry feed.
  • a complete poultry feed can include ingredients such as, but not to be limited to, soybean, corn, wheat, soybean meal, meat and bone meal, fats and oils (e.g., soya oil), limestone, monocalcium phosphate (CaH 4 P 2 O 8 ), sodium bicarbonate (NaHCO3), sodium chloride (NaCl), ammino acids (e.g., L-lysine HCl, DL- methionine, and L-threonine), vitamins (e.g., vitamin A (retinyl-acetate), vitamin D3 (cholecalciferol), vitamin E (DL- ⁇ -tocopherol), vitamin K3 (menadione), vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B6 (pyridoxine-HCL), vitamin B12 (cyanocobalamin), vitamin b3 (niacin), D-pantothenic acid, vitamin B9 (folic acid), vitamin B9 (biotin), salts, organic acids, choline chloride
  • the total protein in the poultry feed can be from about 10 wt.% to about 40 wt.%, from about 12 wt.% to about 35 wt.%, from about 15 wt.% to about 30 wt.%, or from about 16 wt.% to about 26 wt.%.
  • Total protein in the poultry feed can be from 5 wt.%, 6 wt.%, 7 wt.%, 8 wt.%, 9 wt.%, 10 wt.%, 11 wt.%, 12 wt.%, 13 wt.%, 14 wt.%, 15 wt.%, 16 wt.%, 17 wt.%, 18 wt.%, 19 wt.%, 20 wt.%, 21 wt.%, 22 wt.%, 23 wt.%, 24 wt.%, 25 wt.%, 26 wt.%, 27 wt.%, 28 wt.%, 29 wt.%, 30 wt.%, 31 wt.%, 32 wt.%, 33 wt.%, 34 wt.%, 35 wt.%, 36 wt.%, 37 wt.%, 38 wt.%, 39 wt.%,
  • Total protein in the poultry feed can be variable depending on the formulation and intended use of the feed.
  • Total fat (e.g., oil, fat, and/or lipids) in the poultry feed can be from about 0.5 wt.% to about 10 wt.%, from about 1.0 wt.% to about 8 wt.%, from about 1.5 wt.% to about 7 wt.%, or from about 3 wt.% to about 6 wt.%.
  • Total fat in the poultry feed can be from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.25%, 4.5%, 4.75%, 5.0%, 5.25%, 5.5%, 5.75%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, or 10.0% by percent weight of the poultry feed, or can be any amount falling within a range of any of the forgoing.
  • the total fat in the poultry feed can be variable depending on the formulation and intended use of the feed.
  • a poultry feed formulated for a chicken can include from about 1.5 wt.% to about 10.0 wt.% fat.
  • a poultry feed formulated for a turkey can include from about 0.5 wt.% to about 10.0 wt.% fat.
  • the feed additive compositions herein can be any suitable feed product designed for mixing with another composition, such as a base feed, to form the poultry feed.
  • the feed additive composition further can include a premix, a concentrate, a base mix, a supplement, a top dress, or a combination thereof.
  • a base feed can be a commercially available feed or other animal feed.
  • a base feed suitable for poultry can refer to a ration that contains any of the various cereal grains, their byproducts, and other sources of primary nutrition (e.g., fat, starch, and protein) such as barley, blood meal, bone meal, com (e.g., whole or meal), poultry meal, hominy, soybeans (e.g., whole or meal), tallow, wheat (e.g., whole, bran, or middlings), or a combination thereof.
  • primary nutrition e.g., fat, starch, and protein
  • a premix can be a composition that can include vitamins, minerals, appropriate medications, carriers, and combinations thereof, and are typically less than 1 wt.% of the diet but can be higher.
  • the carrier can increase bulk to improve distribution in compounding to prepare a more complete feed material.
  • Such premixes can be used to formulate concentrates and complete feeds.
  • a concentrate can be a composition that can include high-protein feed components and can also include vitamins, minerals, appropriate medications, and combinations thereof.
  • a concentrate is typically 5 wt.% to 40 wt.% of the diet but can be higher or lower.
  • a concentrate can include additives. Concentrates can be used to make complete feeds by adding available grams or other energy sources.
  • An additive can include an ingredient or a chemical preparation or combination of ingredients which is added to the base feed to fulfill a specific nutritional requirement. It can be used in micro quantities and may have no nutritional value but is added to the feed to improve its quality and efficacy .
  • Feed additives can include, but are not limited to, acidifiers, antioxidants, aromatics, deodorizing agents, flavor enhancers, mold inhibitors, pellet binders, preservatives, sweeteners, toxin binders, and the like.
  • a base mix can be similar to a supplement but can contain just a portion of the animal's (e.g., the poultry’s) protein requirements, so it can be used with high protein ingredients and grain (e.g., ground grain and protein source, such as soybean meal) to form the poultry feed.
  • a base mix can include a mixture of one or more macro-mineral sources and one or more micro- ingredient sources such as vitamin premixes, trace mineral premixes, essential ammo acids, and feed additives, that when mixed with sources of protein and energy form a complete feed.
  • a supplement can include a feed ingredient, or a chemical preparation or combination of feed ingredients, intended to supply any deficiencies in an animal (e.g., poultry) feed and/or improve the nutritive balance or performance of the animal or poultry feed.
  • a feed ingredient or a chemical preparation or combination of feed ingredients, intended to supply any deficiencies in an animal (e.g., poultry) feed and/or improve the nutritive balance or performance of the animal or poultry feed.
  • a top dress can include a supplement that can be added at specific time intervals to the bird’s ration to provide a specific supplement or supplements over a time period that makes it inconvenient or difficult to include in a complete feed.
  • the feed additive compositions herein can be added to a premix, a concentrate, a supplement, a top dress, or a base mix that is added to a poultry feed and can be formulated such that the feed additive composition is any suitable proportion of the diet, such as 30 wt.% or less of the poultry feed, or 10 wt.% or less of the poultry feed.
  • the feed additive compositions herein can make up any suitable proportion of the diet, such as from 0. 1 wt.% to 30 wt.%, 1 wt.% to 30 wt.%, 1 wt.% to 15 wt.%, 1 wt.% to 5 wt.%, 15 wt.% to 30 wt.%.
  • the feed additive compositions herein can make up any suitable proportion of the diet, such as from about 1 wt.%, 2 wt.%, 3 wt.%, 4 wt.%, 5 wt.%, 6 wt.%, 8 wt.%, 10 wt.%, 12 wt.%, 14 wt.%, 16 wt.%, 18 wt.%, 20 wt.%, 22 wt.%, 24 wt.%, 26 wt.%, 28 wt.%, or 30 wt.% of the poultry feed, or can be any amount falling within a range of any of the forgoing. It will be appreciated that in some aspects, the feed additive composition can be present at greater than 30 wt.% of the poultry' feed.
  • the feed additive compositions described herein can form any suitable proportion of a poultry feed as a portion of a premix, base mix, concentrate, supplement, top dress, or a combination thereof.
  • the feed additive composition can be about 0.01 wt.% to about 99.9 wt.%, about 0.1 wt.% to about 95 wt.%, or about 0.5 wt.% to about 90 wt.% of the poultry feed, such that the final poultry feed includes 0.01 kg/tonne to 15.0 kg/tonne of the feed additive composition.
  • the amount of microbial fermentate product present in the feed additive compositions and effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa can include a concentration falling within the range from 0.01 kg/tonne to 15.0 kg/tonne.
  • the amount of microbial fermentate product effective to produce a beneficial effect, including improved health measures and enhanced performance measures, in animals coinfected with Clostridium bacteria and Eimeria protozoa can include a concentration falling within a range from 0.01 kg/tonne to 15.0 kg/tonne.
  • the microbial fermentate product can be added to a poultry feed in an amount effective to produce one or more beneficial effects in an animal coinfected with Clostridium bacteria and Eimerict protozoa.
  • the microbial fermentate product can be added to a poultry feed at concentrations including from 0.01 kg/tonne, 0.05 kg/tonne, 0.10 kg/tonne, 0. 15 kg/tonne, 0.20 kg/tonne, 0.25 kg/tonne, 0.30 kg/tonne, 0.35 kg/tonne, 0.40 kg/tonne, 0.45 kg/tonne, 0.50 kg/tonne, 0.55 kg/tonne, 0.60 kg/tonne, 0.65 kg/tonne, 0.70 kg/tonne, 0.75 kg/tonne, 0.80 kg/tonne, 0.85 kg/tonne, 0.90 kg/tonne, 0.95 kg/tonne, 1.0 kg/tonne, 1.25 kg/tonne,
  • the inclusion rate of the microbial fermentate products suitable for use herein can be expressed as kg/tonne, Ib/ton, or wt.%. It will be appreciated that a kg/tonne value can be converted to a wt.% by dividing the kg/tonne value by 1000 and multiplying the resulting value by 100. It will be appreciated that a “tonne” is also referred to in the art as a “metric ton,” where the value of a tonne is equivalent to approximately 1000 kg (i.e., 2204.62 pounds). Unless otherwise noted, as used herein the value for “ton” present in the units Ib/ton is equivalent to approximately 2000 pounds.
  • the microbial fermentate products obtained during of the fermentation of the bacterial strains identified herein can include one or more molecular components, including, but not to be limited to, lipopeptides, polar lipids, isoprenoid-containing compounds, or combination thereof.
  • HPLC high performance liquid chromatography
  • the HPLC process can include detection using ultraviolet (UV) detection methods.
  • UV ultraviolet
  • the molecular components of the microbial fermentate products can be characterized using ultra high-performance liquid chromatography coupled to high-resolution accurate-mass spectrometry (UHPLC-HRAM). Lipopeptides
  • Exemplary lipopeptides present in some of the microbial fermentate products herein can include those falling into the categories of short lipopeptides and long lipopeptides.
  • the short lipopeptides can be characterized as having amino acid sequences of approximately seven amino acid residues covalently linked to lipids having hydrocarbon chains with anywhere from 10-16 carbons in length (i.e., C10-C16). In some aspects, the short lipopeptides can include from five to nine amino acids.
  • the long lipopeptides can be characterized as having amino acid sequences of approximately 10 amino acid residues covalently linked to lipids having hydrocarbon chains with anywhere from 17-20 carbons in length (i.e., C17-C20). In some aspects, the long lipopeptides can include from nine to 14 amino acids. In various aspects, the amino acids in the short lipopeptides or long lipopeptides can include other alkylated amino acids.
  • Exemplary lipopeptides present in some of the microbial fermentate products herein can include, but are not to be limited to, one or more of lipopeptide NO (C50H87N7O13); gageostatin C (C51H89N7O13); surfactin and surfactin variants (C52H91N7O13); neocopiamycin A (C53H93N3O17); [Ile7] -surfactin (C53H93N7O13); fengycin C (C72H110N12O20); SNA-60-367-4 (C73H112N12O20); SNA-60-367-9 (C74H114N12O20); SNA-60-367-13 (C75H116N12O20); or derivatives or isomers thereof.
  • the structures of various lipopeptides found in some of the microbial fermentates herein are presented in Table 1.
  • Exemplary polar lipids present in some of the microbial fermentate products herein can include those that contain long-chain fatty acids with a polar amine-containing or an amide- containing head group.
  • Exemplary polar lipids present in some of the microbial fermentate products herein can include, but are not to be limited to, one or more of N-(3-oxodecanoyl)-L- homoserine lactone (C 14 H 23 NO 4 ); serinolamide C (C 21 H 41 NO 3 ); N-stearoylalanine (C 21 H 41 NO 3 ); L-755807 (C 24 H 35 NO 4 ); aspochalasin J (C 24 H 35 NO 4 ); (4E,6Z)-N-(5-ethyl-5-methyl-2-oxofuran- 3-yl)-8-(3-heptyloxiran-2-yl)-3-hydroxyocta-4,6-dienamide (C 24 H 37 NO 5 );
  • Exemplary isoprenoid-containing compounds present in some of the microbial fermentate products herein can include, but are not to be limited to, one or more of bexarotene (C 24 H 28 O 2 ); 7- ⁇ [(2E,6Z)-3,7,ri-Trimethyl-2,6,10-dodecatrien-l-yl]oxy ⁇ -2H-chromen-2-one (C 24 H 30 O 3 ); diorcinol G (C 24 H 30 O 3 ), ammoresinol (C 24 H 30 O 4 ); cattienoid A (C 24 H 32 O 4 ); bisacremine G (C 24 H 32 O 5 ); neomarinone (C 26 H 32 O 5 ); methyl hydroxy-3, 4-dehydro-apo-8’- lycopenoate (C 31 H 42 O 3 ); kolanone (C 32 H 42 O 4 ); bacillaene (C 34 H 50 N 2 O 6 ); or derivatives or isomers thereof.
  • additional compounds present in some of the microbial fermentate products herein can include but are not to be limited to, vicenistatin M (C 30 H 47 NO 5 ); trienomycin B (C 34 H 48 N 2 O 7 ); prumycin (C 8 H 17 N 3 O 4 ); SF-1902-A3 (C 31 H 55 N 5 O 8 ); or derivatives or isomers thereof.
  • vicenistatin M C 30 H 47 NO 5
  • trienomycin B C 34 H 48 N 2 O 7
  • prumycin C 8 H 17 N 3 O 4
  • SF-1902-A3 C 31 H 55 N 5 O 8
  • the feed additive compositions herein can be formulated for use in any suitable species of poultry and at any suitable life stage.
  • the term “poultry” as used herein refers to domestic fowls, including chickens, turkeys, geese, ducks, ostriches, quails, and pheasants raised to produce meat or eggs.
  • Poultry can include birds characterized as “broilers,” defined as birds reared for meat production, and can also include birds characterized as “layers,” defined as birds reared for laying eggs.
  • Poultry further can include birds characterized as “breeders,” defined as birds that have reached the age of sexual maturity and can lay eggs.
  • the poultry described herein can be selected from the group including a chicken, a turkey, a duck, and a goose. In some aspects, the poultry is a chicken.
  • the terms “chicken,” “broiler chicken,” “broiler,” “layer,” and “bird,” are used interchangeably unless otherwise noted.
  • Chickens (Gallus gallus domesticus) suitable for use in herein can include, but are not limited to, breeds and strains such as Hy-Line, Lohmann, H&N, Hendrix, Ross, Cobb, Hybro, Heritage, Hubbard, ISA, Shaver, Arbor Acres, Indian River, Peterson, and Dekalb.
  • Turkeys (Meleagris gallopavo domesticus) suitable for use herein can include, but are not limited to, breeds and strains such as Broad Breasted White, Nicholas, British United Turkeys, Hybrid Turkeys, Broad Breasted Bronze, and Standard Bronze.
  • the present disclosure provides methods for feeding poultry the feed additive compositions described herein.
  • the methods for feeding poultry can include feeding an animal or group of animals a microbial fermentate product in the feed additive composition in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa to provide a beneficial effect to the poultry.
  • the beneficial effect can be determined as one or more improved health measures or enhanced performance measures, or a combination thereof, in an animal or group of animals coinfected with Clostridium bacteria and Eimeria protozoa.
  • a beneficial effect resulting from an enhancement in performance measures can be a direct result of a beneficial effect due to improved health measures in animals coinfected with Clostridium bacteria and Eimeria protozoa.
  • a beneficial effect resulting from an enhancement in performance measures can be an indirect result of a beneficial effect due to improved health measures in animals coinfected with Clostridium bacteria and Eimeria protozoa.
  • a beneficial effect resulting from an enhancement in performance measures can be a direct or an indirect result, or both, of a beneficial effect due to improved health measures in animals coinfected with Clostridium bacteria. It will be appreciated that the beneficial effects described herein can be observed in poultry having a clinical or subclinical infection with Clostridium bacteria and Eimeria protozoa.
  • animals that are not coinfected with Clostridium bacteria and Eimeria protozoa can also exhibit a beneficial effect when fed the feed additive compositions herein, including one or more improved health measures or enhanced performance measures, or a combination thereof.
  • beneficial effects including one or more improved health measures or enhanced performance measures, or a combination thereof.
  • Producing a beneficial effect in an animal can be a result of the direct or indirect inhibition of the growth of Clostridium bacteria and the reproduction or shedding, or both, of and Eimeria protozoa in response to the administration of the feed additive compositions herein.
  • the beneficial effects against Clostridium bacteria and Eimeria protozoa can be measured in the animal(s) as one or more improved health measures.
  • the improved health measures can include a reduction in the number of necrotic lesions in the animal and a reduction in the severity of the necrotic lesions in the animal.
  • the improved health measures can include a reduction in ceca lesion number, a reduction in ceca lesion severity, a reduction in liver lesion number, and/or a reduction in liver lesion severity, or a combination thereof.
  • the reduction in the number of necrotic lesions in poultry coinfected with Clostridium bacteria and Eimeria protozoa can be compared relative to a corresponding method using poultry feed that does not include the feed additive compositions.
  • the number of ceca lesions and/or liver lesions can be reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 75%, or a range falling within any of the forgoing, as compared to poultry coinfected with Clostridium bacteria and Eimeria protozoa that have not been fed the feed additive compositions.
  • a reduction in lesion severity i.e., a reduction in ceca lesion severity or number and/or a reduction in liver lesion severity or number
  • a reduction in lesion severity in poultry coinfected with Clostridium bacteria and Eimeria protozoa can be determined by scoring the number and severity of lesions present in the liver and ceca of infected birds. Lesion severity for both ceca lesions and liver lesions can be seen as an increase as the lesion score increases from 0 to 4.
  • An exemplary lesion scoring schema is described in Table 5, which can be applied in full or in part depending on which portion of the animal (e.g., ceca, liver, or both) is being analyzed during a course of treatment.
  • ceca lesion severity can be measured as the average ceca lesion score or as the percent of lesions with a high ceca lesion score. For example, more ceca lesions scored as a 0, 1, or 2 as opposed to a 3 or 4, can be an indication of less severe ceca lesions in the poultry.
  • a reduction in ceca lesion severity upon feeding poultry a poultry feed containing the feed additive compositions described herein can be a reduction in average ceca lesion score of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% as compared to poultry fed diet lacking the feed additive compositions.
  • a reduction in ceca lesion severity upon feeding poultry' the feed additive compositions described herein can be a reduction in the percent of ceca lesions scored as a 3 or 4, such that less than 50%, less than 40%, less than 30%, less than 20%, less than 15%, or less than 10% of ceca lesions are scored a 3 or a 4, or such that the percent of ceca legions scored a 3 or 4 is reduced relative to poultry fed a diet lacking a feed additive composition.
  • liver lesion severity can be measured as the average liver lesion score or as the percent of lesions with a high liver lesion score. For example, more liver lesions scored as a 0, 1, or 2 as opposed to a 3 or 4, is an indication of less severe liver lesions in the poultry.
  • a reduction in liver lesion severity upon feeding the poultry a poultry feed containing the feed additive compositions described herein can be a reduction in average liver lesion score of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% as compared to poultry fed a poultry feed lacking the feed additive compositions.
  • a reduction in liver lesion severity upon feeding the poultry the feed additive compositions containing poultry feed described herein can be a reduction in percent of liver lesions scored as a 3 or 4, such that less than 50%, less than 40%, less than 30%, less than 20%, less than 15%, or less than 10% of liver lesions are scored a 3 or a4, or such that the percent of liver legions scored a 3 or 4 is reduced relative to poultry fed a diet without the feed additive compositions.
  • the beneficial effects against Clostridium bacteria and Eimeria protozoa can also be measured in the animal(s) as one or more enhanced performance measures.
  • Poultry fed the feed additive compositions by the methods herein can exhibit enhanced performance measures, including an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination of these traits when coinfected with Clostridium bacteria and Eimeria protozoa
  • the enhanced performance measures in poultry fed the feed additive compositions herein can include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or combinations thereof, relative to poultry fed a feed lacking the feed additive compositions.
  • Birds fed the feed additive compositions by the methods herein further can exhibit prevention of infection with Clostridium bacteria and Eimeria protozoa or improved treatment efficacy and/or reduction of severity of infection when coinfected with Clostridium bacteria and Eimeria protozoa.
  • the enhanced performance measures described herein can be observed in poultry coinfected with Clostridium bacteria and Eimeria protozoa through a challenge in a controlled setting or in poultry coinfected with Clostridium bacteria and Eimeria protozoa via an environmentally acquired infection in their habitat in an amount effective to cause disease in the poultry. It will be appreciated that the enhanced performance measures described herein can be observed in birds fed the feed additive compositions herein even when the birds are not comfected with Clostridium bacteria and Eimeria protozoa in an amount effective to cause disease in the poultry.
  • the methods described herein can increase the weight of poultry fed the feed additive compositions.
  • the weight can be increased by at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 20%, or at least 30%, or any amount falling within a range of the forgoing, relative to poultry fed an equivalent poultry feed lacking the feed additive compositions.
  • the increase in weight can include an average weigh increase of from at least 0.5% to 30%, or from at least 0.5% to 10%, or from at least 10% to 30% in a population of poultry fed the feed additive composition as compared to an average weight in a population of poultry fed a diet lacking the feed additive composition.
  • Weight of individual birds can be measured using standard weighing techniques at any predetermined time interval over the course of the lifespan of the bird.
  • birds can be weighed at birth and then weighed each day following birth until the animal expires.
  • the birds can be weighed twice a day, every other day, weekly, or monthly during the lifespan of the bird.
  • Weight can be compared across treatment groups and to controls not fed the feed additive compositions over one or more time periods during the lifespan of a bird(s). Comparison of weight gain at various time intervals, across treatment groups, and to controls (e.g., both positive and negative controls) can be made to determine the effect of a given feed additive composition on weight gain.
  • the methods described herein can decrease the feed conversion ratio of poultry fed the feed additive compositions.
  • the feed conversion ratio is the measure of an animal(s) efficiency at converting the total amount of feed that the animal(s) consumes over a given period of time against the total weight output (including body mass and/or eggs produced) that the animal(s) gains from consuming the feed during the given period of time.
  • FCR is a unitless value that correlates to the amount of total weight output as measured by body mass and/or eggs produced by the animal(s) fed the feed additive compositions.
  • FCR can be determined using the following formula:
  • FCR ratios for poultry treated with the microbial fermentates herein can include, but are not to be limited to, FCR ratios of from 0.5 to 10, or from 0.5 to 5.
  • the FCR for poultry feed the feed additive compositions herein can be from 1.300 to 1.800.
  • the FCR can be reported as points from 0.5 to 10. It will be appreciated that a lower feed conversion ratio can correlate to a greater efficiency by the animal(s) at converting the total amount of feed consumed over a known period of time into total weight output (e.g., as measured by body mass and/or egg production).
  • the feed conversion ratio can be decreased by at least 0.5%, at least 1.0%, at least 1.5% at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, or at least 10%, or any amount falling within a range of the forgoing, relative to the feed conversion ratio in poultry fed an equivalent poultry feed lacking the feed additive compositions.
  • the decrease in feed conversion ratio can include an average feed conversion ratio decrease of from 0.5% to 10% in a population of poultry fed the feed additive composition as compared to an average feed conversion ratio in a population of poultry fed a diet lacking the feed additive composition.
  • the methods described herein can increase egg production of the poultry.
  • Egg production can be increased by at least 0.5%, at least 1.0%, at least 1.5% at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, or at least 25%, or any amount falling within a range of the forgoing, relative to poultry fed an equivalent feed lacking the feed additive compositions.
  • the increase in egg production can include an average increase of from at least 0.5% to 25%, or from at least 0.5% to 10%, or from at least 10% to 25% in the egg production of a population of poultry fed the feed additive composition as compared to a population of poultry fed a diet lacking the feed additive composition.
  • Egg production can be calculated over the course of the lifespan of the birds being fed the feed additive compositions herein.
  • Egg production can be determined by monitoring and recording the number of eggs laid by each individual bird or of the number of eggs laid by the entire flock of birds.
  • the number of eggs laid by each individual bird, or the entire flock of birds can be recorded once a day, every other day, weekly, or monthly during the lifespan of the birds.
  • Comparison of egg production at various intervals, across treatment groups, and to controls can be made to determine the effect of a given feed additive composition on egg productivity.
  • L0076J The methods described herein can decrease mortality of the poultry.
  • Mortality can be decreased by at least 0.5%, at least 1.0%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, or at least 40%, or any amount falling within a range of the forgoing, relative to poultry fed an equivalent poultry feed lacking the feed additive compositions.
  • the decrease in mortality can include an average decrease of from at least 0.5% to 40%, or from at least 0.5% to 10%, or from at least 10% to 40% in the mortality of a population of poultry fed the feed additive composition as compared to a population of poultry fed a diet lacking the feed additive composition.
  • Mortality can be monitored over the course of a lifespan of the birds being fed the feed additive compositions herein. Mortality' can be recorded as the death of one bird or a percentage of a population of birds. Comparison of mortality at various intervals, across treatment groups, and to controls (e.g., both positive and negative controls) can be made to determine the effect of a given feed additive composition on mortality over the course of a treatment.
  • the methods described herein can decrease morbidity in the poultry.
  • morbidity can be decreased by at least 0.5%, at least 1.0%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, or at least 40%, or any amount falling within a range of the forgoing, relative to poultry fed an equivalent poultry feed lacking the feed additive compositions.
  • the decrease in morbidity can include an average decrease of from at least 0.5% to 40%, or from at least 0.5% to 10%, or from at least 10% to 40% in the morbidity of a population of poultry fed the feed additive composition as compared to a population of poultry fed a diet lacking the feed additive composition.
  • Morbidity can be monitored over the course of a lifespan of the birds being fed the feed additive compositions herein.
  • Morbidity can include the incidence of one or more type of illness identified by various symptoms of necrotic enteritis or other illness, including but not to be limited to, inactivity, listlessness, diarrhea, bloody stools, lesions, cloudy eyes, pus in the eyes, tissue mass, scaly legs, loss of appetite, respiratory distress, paralysis, and the like.
  • Morbidity' can be recorded as symptomatic illness in one bird or a percentage of a population of birds exhibiting symptomatic illness. Comparison of morbidity at various intervals, across treatment groups, and to controls (e.g., both positive and negative controls) can be made to determine the effect of a given feed additive composition on morbidity.
  • Feeding poultry with the feed additive compositions can begin upon hatching and can extend throughout an animal’s lifecycle. Feeding poultry the feed additive compositions can also be performed over a narrower time span or life stage. It will be appreciated that the feed additive compositions can be administered as a daily feed ration that is fed to the poultry on most days or on all days. In various aspects, the feed additive composition can be administered to the poultry one, two, three, four, five, six, or seven days of the week, or a range falling within any of the forgoing, for a predetermined time span, or for the life of the animal.
  • the feed additive compositions herein can be fed to the animal(s) during any of its discrete life stages, throughout the lifespan of the animal, or only when the animal has an active infection.
  • the feed additive compositions can be fed at any inclusion rate described herein to an animal throughout the duration of an active infection and until the infection is cleared, where the animal can then be switched back to a diet that lacks the feed additive compositions.
  • the feed additive compositions herein can be fed prophylactically to the animals to prevent disease.
  • the feed additive compositions herein can be fed prophylactically to the animals at a first inclusion rate, and if the animals become infected with a pathogen the animal could be switched to a diet including a feed additive composition at a second inclusion rate, where the second inclusion rate is higher than the first inclusion rate.
  • the animal can be returned to a diet at a first inclusion rate or a diet having no feed additive composition included therein.
  • the first inclusion rate and second inclusion rate can include any inclusion rate or a range of inclusion rates as described elsewhere herein.
  • the methods herein can include feeding poultry a feed additive composition directly and/or feeding poultry a poultry feed containing the feed additive composition.
  • the feed additive compositions fed to the poultry can include one or more microbial fermentate products, or it can include one or more microbial fermentate products plus other components as described elsewhere herein.
  • the methods of feeding the poultry herein can inhibit the growth of Clostridium bacteria and the reproduction and shedding, or both, of Eimeria protozoa in the poultry.
  • the amount of feed additive composition can be determined based on the concentration of microbial fermentate product required to provide an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa, such as directly or indirectly inhibiting the growth of Clostridium perfringens and the reproduction or shedding, or both, of Eimeria protozoa.
  • the methods using the feed additive compositions herein can provide various advantages to poultry as compared to corresponding methods using poultry feed that does not include the feed additive compositions.
  • the methods using the feed additive compositions herein can produce a beneficial effect in an animal fed the feed additive composition as observed relative to poultry fed a diet lacking the feed additive composition.
  • the methods herein can include any suitable methods of admimstenng the feed additive compositions to poultry.
  • the methods herein are directed to administering the feed additive compositions chickens or turkeys.
  • the methods can include mixing the feed additive compositions with a base feed, a premix, a concentrate, a base mix, a supplement, a top dress, or a combination thereof as described elsewhere herein, and providing the mixture to poultry for ingestion.
  • the methods can include administering the feed additive compositions directly to poultry for ingestion.
  • the methods can include administering a feed additive composition at a concentration in an amount effective to produce an inhibitory effect against Clostridium bacteria in a range from 0.01 kg/tonne, 0.05 kg/tonne, 0.10 kg/tonne, 0.15 kg/tonne, 0.20 kg/tonne, 0.25 kg/tonne, 0.30 kg/tonne, 0.35 kg/tonne, 0.40 kg/tonne, 0.45 kg/tonne, 0.50 kg/tonne, 0.55 kg/tonne, 0.60 kg/tonne, 0.65 kg/tonne, 0.70 kg/tonne, 0.75 kg/tonne, 0.80 kg/tonne, 0.85 kg/tonne, 0.90 kg/tonne, 0.95 kg/tonne, 1.0 kg/tonne, 1.25 kg/tonne, 1.5 kg/tonne,
  • the methods can include use of a feed additive compositions in the diet of an animal at an inclusion rate that can include more than 15.0 kg/tonne feed additive composition as long as the inclusion rate does not preclude the animal from being supplied the nutritional requirements necessary to promote and maintain the normal growth and health of the animal.
  • the methods herein can include inhibiting the growth of Clostridium bacteria and inhibit the reproduction and shedding of Eimeria protozoa in poultry.
  • the methods can include feeding poultry by administering the feed additive composition containing a microbial fermentate product to the poultry.
  • the microbial fermentate product can be present in the feed additive compositions administered to the poultry in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa, where the inhibitory effect results in one or more beneficial effects for the poultry.
  • the feed additive compositions can be administered to poultry in an amount effective to directly or indirectly inhibit the growth of Clostridium bacteria.
  • the Clostridium bacteria include one or more of Clostridium baratii, Clostridium botulinum, Clostridium colinum, Clostridium difficile, Clostridium fallax, Clostridium perfringens, and Clostridium septicum.
  • the feed additive compositions further can be administered to poultry in an amount effective to directly or indirectly inhibit the reproduction or shedding of Eimeria protozoa, including, but not to be limited to Eimeria acervulina, Eimeria brunetti, Eimeria hagani, Eimeria maxima, Eimeria mitis, Eimeria mivati, Eimeria necatrix, Eimeria praecox, or Eimeria tenella.
  • the methods described herein can reduce or prevent a Clostridium and Eimeria coinfection in poultry.
  • Administering the feed additive composition containing a microbial fermentate product to the poultry as described herein can reduce or prevent a Clostridium and Eimeria coinfection in the poultry.
  • the microbial fermentate product can be present in the feed additive compositions administered to the poultry in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa, where the inhibitory effect results in one or more beneficial effects for the poultry.
  • the incidence of an infection in the poultry can be reduced relative to incidence of an infection in poultry fed a poultry feed lacking the feed additive compositions.
  • incidence of Clostridium and Eimeria coinfection can be reduced at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, or any amount falling within a range of the forgoing, as compared to the incidence of infection in poultry fed a feed lacking the feed additive compositions.
  • the incidence of Clostridium and Eimeria coinfection can be reduced to more than 70%.
  • the methods described herein can treat or reduce the severity of a Clostridium and Eimeria coinfection.
  • Administering the feed additive composition containing a microbial fermentate product to the poultry as described herein can reduce the severity of a Clostridium and Eimeria coinfection in the poultry.
  • the microbial fermentate product can be present in the feed additive compositions administered to the poultry in an amount effective to produce an inhibitory effect against Clostridium bacteria and Eimeria protozoa, where the inhibitory effect results in one or more beneficial effects for the poultry.
  • the severity of a Clostridium and Eimeria coinfection can be measured as the mortality rate, or culling rate, of birds coinfected with Clostridium bacteria and Eimeria protozoa.
  • a reduction in the mortality rate can indicate a reduction in the severity of a Clostridium and Eimeria coinfection.
  • the methods described herein can treat a Clostridium and Eimeria coinfection in poultry by reducing one or more symptoms of the infection, reducing mortality rate, reducing the morbidity rate, or increasing the number of birds that clear the infection.
  • the methods described herein include a method for enhancing performance measures in poultry. The method can include administering a feed additive composition including a microbial fermentate product to poultry, where the microbial fermentate product is present in the feed additive composition in an amount effective for enhancing performance measures in the poultry.
  • the method includes enhancing performance measures in poultry that are coinfected with Clostridium perfringens and one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella.
  • the enhanced performance measures include an increase in weight, a decrease in feed conversion ratio, an increase in egg production, a decrease in mortality, a decrease in morbidity, or any combination thereof. The enhanced performance measures are described in more detail elsewhere herein.
  • the methods herein can include challenging a population of poultry' with Clostridium perfringens and one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella.
  • the challenge can include administering the Clostridium perfringens in an amount of from 1.0 x 10° to 1.0 x 10 10 colony forming units (CFU) in a dietary ration of an animat or from 1.0 x 10 3 to 1.0 x 10 9 , or from 1.0 x 10 8 to 60.0 x 10 8 CFU in 1-3 ml volumes mixed into from 15 to
  • the methods can include challenging a population of poultry with Clostridium bacteria at an amount of from at least 1.0 x 10° CFU, at least 1.0 x 10 1 CFU, at least 1.0 x 10 2 CFU, at least 1.0 x 10 3 CFU, at least 1.0 x 10 4 CFU, at least 1.0 x 10 5
  • the poultry feed used to deliver the dose of Clostridium perfringens does not contain a feed additive composition.
  • the dose of Clostridium perfringens can be administered during a challenge of a population of poultry in a way that it is not included in a daily ration.
  • the dose of Clostridium perfringens can be administered directly to each bird in an enclosure, such as via oral gavage.
  • the dose of Clostridium perfringens can be administered directly to a predetermined number of birds per enclosure, where those birds are then returned to the enclosure with any remaining non-infected birds, and where the directly infected birds act as seeder birds that then go on to infect the remainder of birds in the enclosure through direct contact or through indirect contact such as through excrement in the environment. It will be appreciated that challenging a population of poultry can be performed using any strain of Clostridium bacteria, or mixtures thereof, as described elsewhere herein.
  • the challenge further can include challenging a population of poultry with one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella at an amount of from of from 1.0 x 10° to 1.0 x 10 10 , or from 1.0 x 10 3 to 1.0 x 10 9 sporulated oocysts or sporozoites in a dietary ration of an animal, or from 1.0 x 10 8 to 60.0 x 10 8 sporulated oocysts or sporozoites in 1-3 ml volumes mixed into from 15 to 30 grams of poultry feed per bird.
  • the methods can include challenging a population of poultry with one or more of Eimeria acervulina, Eimeria maxima, or Eimeria tenella at an amount of from 1.0 x 10°, at least 1.0 x 10 1 , at least 1.0 x 10 2 , 1.0 x 10 3 CFU, at least 1.0 x 10 3 , at least 1.0 x 10 4 , at least 1.0 x 10 5 , at least 1.0 x 10 6 , at least 1.0 x 10 7 , at least 1.0 x 10 8 , at least 1.5 x 10 8 , at least 2.0 x 10 8 , at least 2.5 x 10 8 , at least 3.0 x 10 8 , at least 3.5 x 10 8 , at least 4.0 x 10 8 , at least 4.5 x 10 8 , at least 5.0 x 10 8 , at least 5.5 x 10 8 , at least 6.0 x 10 8 , at least 6.5 x 10 8 , at least 7.0 x
  • the dose of Eimeria protozoa can be administered during a challenge of a population of poultry in a way that it is not included in a daily ration.
  • the dose of Eimeria protozoa can be administered directly to each bird in an enclosure, such as via oral gavage.
  • the dose of Eimeria protozoa can be administered directly to a predetermined number of birds per enclosure, where those birds are then returned to the enclosure with any remaining non-infected birds, and where the directly infected birds act as seeder birds that then go on to infect the remainder of birds in the enclosure through direct contact or through indirect contact such as through excrement in the environment.
  • 100921 Challenging a population of poultry with Clostridium perfringens can include administering an amount of from 1.0 x 10° to 1.0 x 10 10 colony forming units (CFU) in a dietary ration of an animal, of from 1.0 x 10 3 CFU to 1.0 x 10 9 CFU, or from 1.0 x 10 8 CFU to 60.0 x 10 8 CFU of Clostridium perfringens, and an amount of from 1.0 x 10° to 1.0 x 10 10 sporulated oocysts or sporozoites, of from 1.0 x 10 3 to 1.0 x 10 9 sporulated oocysts or sporozoites, or from 1 0 x 10 8 to 60.0 x 10 8 sporulated oocysts or sporozoites of Eim
  • CFU colony forming units
  • the birds can be allowed to consume the mixture for anywhere from 0.5 to 4 hours post administration and then returned to the diet containing the feed additive compositions.
  • the birds can have their feed trays emptied for 0 to 8 hours prior to administration of the mixture containing Clostridium perfringens and Eimeria protozoa.
  • a challenge with Clostridium bacteria and Eimeria protozoa can include a challenge in a controlled setting where the bacteria are administered directly to the poultry. While in some aspects herein poultry can acquire an infection during a challenge in a controlled setting, in other aspects the poultry treated with the feed additive compositions herein can acquire an infection with Clostridium bacteria and Eimeria protozoa in their habitat.
  • Clostridium bacteria and Eimeria protozoa can include those acquired in the animals’ habitat where the bacteria are ingested in an amount effective to cause disease in the animal(s).
  • the beneficial effects described using the feed additive compositions herein can be observed in poultry coinfected with Clostridium bacteria and Eimeria protozoa through a challenge in a controlled setting and in poultry coinfected with Clostridium bacteria and Eimeria protozoa via an environmentally acquired infection in their habitat in an amount effective to cause disease in the poultry.
  • the infections herein with Clostridium bacteria and Eimeria protozoa can include those that are subchnical or clinical.
  • Bacterial and fungal strains for generating the microbial fermentate products herein include one or more of: Acetobacter okinawensis, Acetobacter pasteurianus, Acetobacter peroxydans, Acetobacter okinawensis, Acidipropionibacterium acidipropionici, Arxula adeninivorans, Bacillus altitudinis, Bacillus atrophaeus, Bacillus aryabhattai, Bacillus cercus, Bacillus coagulans, Bacillus halotolerans, Bacillus megaterium, Bacillus pumilis, Bacillus safensis, Bacillus subtilis, Bacillus velezensis, Bacillus xiamenensis, Brevibacillus laterosporus, Candida carpophila, Candida fermentati, Debaryomyces hansenii, Enterococcus mundtii, Kazachstania martiniae, Lactobac
  • microbial derived fermentates of the various microbial strains described in Example 1 were prepared in 250 ml baffled shake flasks as follows. Bacterial cultures were grown in TSB (Tryptic Soy Broth) containing the following composition: BactoTM Tryptone (Pancreatic Digest of Casein, Thermo Fisher Scientific, Waltham, MA, USA) 17.0 g/L, BactoTM Soytone (Peptic Digest of Soybean Meal, Thermo Fisher Scientific, Waltham, MA USA) 3.0 g/L, glucose 2.5 g/L, sodium chloride 5.0 g/L, and dipotassium hydrogen phosphate 2.5 g/L.
  • TSB Traptic Soy Broth
  • Seed culture medium was inoculated with fresh biomass from a single colony sampled from prepared agar plates using an inoculation loop. Seed cultures were incubated for 18-24 hours in a shaker at 250 rpm, 30 °C, and 75% humidity. Any fungal-denved fermentates using the various microbial strains described in Example 1 were prepared in YPD Medium (Yeast Extract Peptone Dextrose, Thermo Fisher Scientific, Waltham, MA USA) unless otherwise indicated.
  • YPD Medium Yeast Extract Peptone Dextrose, Thermo Fisher Scientific, Waltham, MA USA
  • Working cultures for obtaining fermentates were generated using 250 ml baffled shake flasks containing 50 ml of TSB medium that were inoculated at initial ODeoo (i.e., optical density at 600 nm) of 0.1 using an inoculum from the overnight seed cultures.
  • Working cultures were incubated on an agitation shaker at 250 rpm, 30 °C, and 75% humidity for 24 hours. After 24 hours, the agitation was turned off in the shaker and the cultures were incubated for an additional 24 hours. After 48 hours post inoculation, the 250 ml flasks were removed from the shaker and heated to 60 °C and held at that set point for one hour to heat inactivate the microbial culture biomass.
  • Fermentates were packaged and stored at -80 °C until further chemical and biological characterization. Upon use in the in vitro analyses herein, the fermentates were thawed and heated to 75 °C for 15 min for an additional heat inactivation step. The contents were then split between 4 tubes, vortexed, and used immediately or stored at -20 °C for additional future use and testing.
  • the assay described in this example includes a single dose screening assay that evaluates the effects of various bacterial fermentates against Clostridium perfringens using the bacterial strains described in Example 1 and prepared according to Example 2.
  • Two multi-drug resistant strains of Clostridium perfringens, referred to herein as multi-drug resistant strain 1 and multi-drug resistant strain 2 were assayed.
  • Clostridium perfringens bacterial cultures were prepared in 250 ml baffled shake flasks containing 50 ml of sterile Clostridial Differential Broth (CDB) (Thermo Fisher Scientific, Waltham, MA USA). The flasks were inoculated using a single colony that was picked from a culture plate, and grown overnight for 18-24 hours in an anaerobic chamber supplemented with 85% N, 10% CO 2 and 5% H at 250 rpm and 39 °C. Following incubation, the culture was diluted to an OD 600 of 0.1 in sterile CDB medium using a clean cuvette in an optical spectrophotometer.
  • CDB Clostridial Differential Broth
  • Each well of the first row of a 96-well round bottom microtiter plate was prepared with 160 pl of sterile CDB medium.
  • a 20 pl aliquot at a 1:10 ratio, or 0.1 dilution i.e., 10 percent volume (10% v/v)
  • 0.1 dilution i.e. 10 percent volume (10% v/v)
  • Approximately 5 x 10 4 CFU of Clostridium perfringens in 10 pl of sterile CDB medium was added to each well.
  • Control samples were included in the assays as a non-inoculated dilution senes containing no fermentate.
  • a “negative control plate” without bacterial culture was also included to monitor for sterility.
  • the bacterial fermentates tested in this example exhibited a minimum of a 1-log reduction in colony forming units (CFU) against Clostridium perfringens growth when compared to an untreated control. In many cases, the bacterial fermentates exhibited a minimum of a 2-log reduction in colony forming units (CFU) against Clostridium perfringens growth when compared to an untreated control. Results reported herein were conducted using multi-drug resistant strain
  • the assay described in this example includes a dose titration assay that evaluates the minimum inhibitory concentrations of bacterial fermentates required to inhibit Clostridium perfringens growth using fermentates from bacterial strains as described in Example 1 and prepared according to Example 2. Both multi -drug resistant strain 1 and multi -drug resistant strain
  • Clostridium perfringens bacterial cultures were initiated using one or more colonies that were picked from a culture plate and placed into in 250 ml baffled shake flasks containing 50 ml of sterile Clostridial Differential Broth (CDB) (Thermo Fisher Scientific, Waltham, MA USA) and grown overnight in an anaerobic chamber supplemented with 85% N, 10% CO2 and 5% H at 39 °C. The culture was diluted to an ODeoo of 0.1 in sterile CDB medium using a clean cuvette and an optical spectrophotometer.
  • CDB Clostridial Differential Broth
  • Each well of a 96-well round bottom microtiter plate was prepared for the bacterial fermentates.
  • the bacterial fermentates were added to individual wells of the first column of the 96-well plate in the following volumes (percent volume (% v/v) for final dilutions in parenthesis): 80 pl (40% v/v dilution), 40 pl (20% v/v dilution), 20 pl (10% v/v dilution), 10 pl (5 % v/v dilution), 5 pl (2.5 % v/v dilution) and 2.5pl (1.25 % v/v dilution).
  • Respective amounts of sterile CDB medium to bring the volume up to 100 pl were added to each well to achieve the recited dilutions.
  • the bacterial fermentates added to column 1 were mixed thoroughly five to six times with the CDB medium.
  • 100 pl of the mixture in column 1 was transferred to 100 pl of sterile CDB medium in column 2 and mixed thoroughly as before.
  • 100 pl of the mixture in column 2 was transferred to 100 pl of sterile CDB medium in column 3 and mixed thoroughly as before.
  • the dilution procedure was repeated through column 6. Upon reaching column 6, the mixture was mixed thoroughly and 100 pl of the mixture was discarded before proceeding.
  • the bacterial fermentates tested in this example exhibited a minimum of a l-log reduction in colony forming units (CFU) against Clostridium perfringens growth when compared to an untreated control. In many cases, the bacterial fermentates exhibited a minimum of a 2-log reduction in colony forming units (CFU) against Clostridium perfringens growth when compared to an untreated control. Results reported herein were conducted using multi-drug resistant strain 1 of Clostridium perfringens. Similar results were reported (not shown) for multi-drug resistant strain 2 of Clostridium perfringens.
  • Example 5 Preparation of 2L Microbial Fermentates for In Vivo Analysis
  • bacterial derived fermentates of the various bacterial strains described in Example 1 were prepared in a 2 L stirred bioreactor as follows. Bacterial cultures were grown in TSB (Tryptic Soy Broth) containing the following composition: BactoTM Tryptone (Pancreatic Digest of Casein, Thermo Fisher Scientific, Waltham, MA USA) 17.0 g/L, BactoTM Soytone (Peptic Digest of Soybean Meal, Thermo Fisher Scientific, Waltham, MA USA) 3.0 g/L, glucose 2.5 g/L, sodium chloride 5.0 g/L, and dipotassium hydrogen phosphate 2.5 g/L.
  • Seed culture medium was inoculated with fresh biomass of a single colony from prepared agar plates using an inoculation loop. Seed cultures were incubated for 18-24 hours in a shaker at 250 rpm, 30 °C and 75% humidity.
  • Working cultures for obtaining fermentates were generated using 2 L stirred bioreactors containing 2 L of TSB medium that were inoculated at initial ODeoo of 0.1 using an inoculum from the overnight seed cultures.
  • Working cultures were incubated in the stirred bioreactor at 700 revolutions per minute (rpm) while aerated, with a gas flow rate of 0.25 VVM (vessel volume per minute; i.e., 0.5 SLMP (standard liters per minute)), at 30 °C for 24 hours.
  • VVM vessel volume per minute; i.e., 0.5 SLMP (standard liters per minute)
  • a 50% solution of anti-foaming agent (Ivanhoe 1163B, Ivanhoe Industries, Inc.; Zion, Illinois, USA) was added to the bioreactor at a 0.1% flow rate during the incubation to prevent excess foaming in the bioreactor vessel. After 24 hours, the agitation and aeration were turned off in the bioreactor and the cultures were incubated for an additional 24 hours. After 48 hours post inoculation, 2 L vessels were heated to 60 °C and held at that set point for one hour to heat inactivate the microbial culture biomass. Fermentates were packaged and stored at -80 °C until further chemical and biological characterization.
  • each bacterial fermentate was mixed with a soy hull (or other suitable) carrier in a 1: 1 ratio on a dry matter basis.
  • the soy hulls were sized at approximately 1.0 mm in diameter.
  • the bacterial fermentates were then individually mixed thoroughly and dried in an oven at 60 °C Drying time varied between 24 hours to up to 5 days depending on volume of bacterial fermentate to be dried. After incubation, the dried fermentate mixture was ground using a grinder equipped with a 0.5 mm screen until uniform consistency was achieved.
  • a tracer compound such as a metal oxide
  • a tracer compound was added at to the dried bacterial fermentate compositions of approximately 5 g per inclusion rate of product.
  • Fully dried bacterial fermentates were stored in polymeric air-tight packaging, labeled, and stored in a -20 °C freezer until use.
  • Example 6 Analysis of Microbial Fermentates on Clostridium Perfrinsens Reduction Using an Infection Model in Broiler Chickens
  • Assays described in this example evaluated the effects of bacterial fermentates from Bacillus velezensis, Pediococcus pentosaceus, and Lactobacillus plantarum on Clostridium Perfringens infection reduction in broiler chickens.
  • the groups included an unchallenged negative control group (CON); a challenged, positive control group (POS); an antibiotic control group challenged and treated with the antibacterial BMD® (Bacitracin-Methylene-Disalicylate; Zoetis, USA); a challenged group treated with Bacillus velezensis fermentate; a challenged group treated with Lactobacillus pediococcus fermentate; and a challenged group treated vcdh Lactobacillus plantarum fermentate.
  • CON unchallenged negative control group
  • POS positive control group
  • BMD® Bacillus velezensis fermentate
  • Lactobacillus pediococcus fermentate a challenged group treated vcdh Lactobacillus plantarum fermentate.
  • the birds were vaccinated for Mareks upon hatching. On study day zero (DO), the birds were vaccinated for
  • Feed Conversion Rate (FCR)' Results indicate that negative control birds had significantly improved FCR compared to challenged groups at all time intervals containing challenge periods after Day 14. No significant differences were observed in FCR at any time interval across challenged groups, except that birds that received the Lactobacillus plantarum fermentate had significantly higher FCR from Day 0-28 and Day 14-28. The FCR was adjusted for mortality within each treatment group. FCR results are outlined in Table 11. Table 11. FCR for All Treatment Groups
  • Livability (%) No significant differences were observed at any time intervals across treatment groups.
  • Lesion Score Results indicate that the positive control challenge birds had significantly higher lesion scores than the negative control birds (i.e., 1. 19 ⁇ 0.07 vs. 0.00). Birds that received the Bacillus velezensis fermentate and the Lactobacillus pediococcus fermentate had significantly reduced lesion scores compared to the positive control challenged birds (i.e., 0.75 ⁇ 0 09 and 0.78 ⁇ 0.10 vs. 1.19 ⁇ 0.07, respectively). The birds that received BMD® antibiotic treatment had numerically but not statistically significant lower lesion scores than the positive control challenged birds (i.e., 1.08 ⁇ 0.078 vs. 1.19 ⁇ 0.07). Birds that received the Bacillus velezensis fermentate and the Pediococcus pentosaceus fermentate had lesion scores that were significantly lower than BMD® treated birds. Lesion scores are outlined in Table 12.
  • Eimeria oocysts were prepared for analysis to determine the effects of fermentates on various types of Eimeria protozoa.
  • the remaining sediment was washed by being resuspend in water, centrifuged for 1600 x g for 5 minutes and the supernatant discarded. The remaining sediment was resuspended in 2.5% (w/v) potassium di chromate solution and 1% antibiotics. Washed oocysts were stored at 4 °C until ready for use
  • a trypan blue staining assay was performed to analyze Eimeria viability following incubation with microbial fermentates.
  • the trypan blue staining assay allows for a direct identification and enumeration of Eimeria protozoa at various life cycle phases. Viability of Eimeria oocysts can be detennined by trypan blue exclusion from the interior of the oocyst.
  • a viable oocyst has a clear cytoplasm in the presence of trypan blue, whereas a nonviable oocyst has a blue cytoplasm in the presence of trypan blue stain.
  • Trypan blue exclusion staining can be utilized to stain Eimeria protozoa at various life stages, including but not to be limited to oocysts, sporocysts, and sporozoites.
  • Fermentates were thawed from individual 100 pl stocks and filter sterilized with a 0.2-micron polyethylene terephthalate (PET) filter. Each well was brought to a total volume of 200 pl by adding 170 pl of sterile PBS and 20 pl of each sterilized fermentate in duplicate. A total of 343 fermentates were assayed. Control wells were included as follows: PBS only, fermentate alone, and untreated oocysts with and without trypan blue exclusion dye.
  • PET polyethylene terephthalate
  • Complete sporulation consists of four sporocyst, each containing two sporozoites. Once sporulation reached at least 85% sporulation, oocysts were stored at 4 °C prior to cleaning.
  • HBSS Hank’s Balanced Salt Solution
  • Isolation and purification of sporozoites The oocyst suspension was counted using a hemocytometer, and the number required for the assay were removed (approximately 2 x 10 6 oocysts). The oocysts were placed into a 2 mL round bottom centrifuge tube and were centrifuged for 30 seconds at 10,000 x RCF to pellet the oocysts. The pelleted oocysts was suspended in 1 mL HBSS and 0.25 mL - 0.5 mL of 0.5 mm diameter (Jencons, No 8. Ballottini) glass beads were added. The tube was placed into a bead beater for 10 seconds.
  • sporozoites For excystation of the sporozoites, 0.25-0.5% (w/v) Trypsin, 1% taurocholic acid, and 0.3% bile salts were added to the sporozoites, which were then incubated at 39-41 °C for 60- 90 minutes, depending on species. The sporozoites were checked every 30 minutes to determine when most of the sporozoites were free. The sporozoites and debris were washed in Dulbecco’s Modified Eagles Medium (DMEM) (Dulbecco’s, Fischer Scientific) and centrifuged as before to remove excess trypsin. The washing and centrifugation were performed two times, to form pelleted sporozoites. Once recovered, the sporozoites were utilized in assays in the same day.
  • DMEM Modified Eagles Medium
  • Results indicate that the fermentates showed inhibitory effects against the Eimeria tenella sporozoites after incubation using the tracking software to track and analyze the movement and activity of the sporozoite as compared to the control.
  • bacterial derived fermentates of the various bacterial strains described in Example 1 were prepared in a 20 L stirred bioreactor as follows. Bacterial cultures were grown in TSB (Tryptic Soy Broth) containing the following composition: BactoTM Tryptone (Pancreatic Digest of Casein, Thermo Fisher Scientific, Waltham, MA USA) 17.0 g/L, BactoTM Soytone (Peptic Digest of Soybean Meal, Thermo Fisher Scientific, Waltham, MA USA) 3.0 g/L, glucose 2.5 g/L, sodium chloride 5.0 g/L, and dipotassium hydrogen phosphate 2.5 g/L.
  • Seed culture medium was inoculated with fresh biomass of a single bacterial colony from prepared agar plates using an inoculation loop. Seed cultures were incubated for 18-24 hours in a shaker at 250 rpm, 30 °C and 75% humidity.
  • Fungal derived fermentates of the various microbial strains described in Example 1 were prepared in a 20 L stirred bioreactor as follows.
  • yeast cultures were grown in YPD Medium (Yeast Extract Peptone Dextrose, Thermo Fisher Scientific, Waltham, MA USA). Overnight seed cultures were generated using 500 ml baffled shake flasks with 100 ml of YPD medium. Seed culture medium was inoculated with fresh biomass of a single yeast colony from prepared agar plates using an inoculation loop. Seed cultures were incubated for 18-24 hours in a shaker at 250 rpm, 30 °C and 75% humidity.
  • Working bacterial cultures for obtaining bacterial fermentates were generated using 20 L stirred bioreactors containing 18 L of TSB medium with 0.6% airflow that were inoculated at initial ODeoo of 0. 1 using an inoculum from the overnight seed cultures.
  • Working bacterial cultures were incubated in the stirred bioreactor at 500 revolutions per minute (rpm), with a gas flow rate of 0.25 VVM (vessel volume per minute; i.e., 4.5 SLMP (standard liters per minute)), at 30 °C for 24 hours.
  • a 50% solution of anti-foaming agent (Ivanhoe XFO-324K, Ivanhoe Industries, Inc.; Zion, Illinois, USA) was added to the bioreactor at a 0.1% flow rate during the incubation to prevent excess foaming in the bioreactor vessel. Cultures were allowed to mature for an additional 24 hours at 30 °C with no agitation and no airflow.
  • Working yeast cultures for obtaining yeast fermentates were generated using 20 L stirred bioreactors containing 18 L of YPD medium that were inoculated at initial ODeoo of 0.1 using an inoculum from the overnight seed cultures.
  • Working yeast cultures were incubated in the stirred bioreactor at 500 revolutions per minute (rpm), with a gas flow rate of 0.25 VVM (vessel volume per minute; i.e., 4.5 SLMP (standard liters per minute)), at 30 °C for 24 hours.
  • a 100% solution of XFO-324K anti-foaming agent (Ivanhoe Industries, Inc.; Zion, Illinois, USA) was added to the bioreactor including a feedback probe having low to medium sensitivity with a flow pump at 10 % flow rate for 5 second periods during the incubation to prevent excess foaming in the bioreactor vessel.
  • the 18 L volumes of bacterial or yeast fermentates were dried and prepared for storage until use in animal studies. Before drying, each fermentate was mixed with a soy hull (or other suitable) carrier in a 1 : 1 ratio on a dry matter basis. The soy hulls were sized at approximately 1 0 mm in diameter. The fermentates, were then individually mixed thoroughly and dried in an oven at 60 °C. Drying time varied between 24 hours to up to 5 days depending on volume of each fermentate to be dried. After incubation, the dried fermentate mixture was ground using a grinder equipped with a 0.5 mm screen until uniform consistency was achieved.
  • a tracer compound such as a metal oxide
  • a tracer compound was added at to the dried fermentate compositions of approximately 5 g per inclusion rate of product.
  • Fully dried fermentates were stored in polymeric air-tight packaging, labeled, and stored in a -20 °C freezer until use.
  • Example 11 In vivo Analysis of Microbial Fermentates on Eimeria Reduction Using an Infection Model in Broiler Chickens
  • Broiler chickens (Cobb 500, Cobb-Vantress Inc.) will be separated into by treatment groups, each treatment group starting with 18 chickens on day zero (DO).
  • the treatment groups will be replicated into 12 cages with a total of 216 birds per treatment group.
  • On day 7, the birds will be counted and adjusted to 16 birds per pen, where any extra birds will be removed, weighed, and recorded.
  • the birds will be vaccinated for Mareks upon hatching.
  • DO study day zero
  • the birds On study day zero (DO), the birds will be vaccinated for Newcastle disease, infectious bronchitis, and coccidiosis by spray application using a spray cabinet.
  • Each Treatment Group is outlined in Table 13.
  • the birds are provided water and feed ad libitum throughout the study unless otherwise noted.
  • the birds will be observed twice daily for clinical symptoms, and weights of each chicken were recorded on days 0, 14, 28, and 35.
  • Feed will be included in the diet for each treatment group from day 0 of the study.
  • the feed will be weighed in on day 0 and non-consumed feed weighed on days 14, 28, and 35.
  • Feed intake will be calculated from days 0-14, 14-28, 0-28, 0-35, and 28-35.
  • An unmedicated commercial type chicken starter compounded with feedstuffs commonly used in the United States is formulated for daily use as a basal starter feed.
  • Experimental treatment feeds are prepared from the basal starter feed. Quantities of all basal feed and test articles used to prepare treatment batches will be documented. Treatment diets are mixed to assure a uniform distribution of respective fermentate.
  • Average bird weight per pen on days 14, 28, and 35 are to be calculated.
  • the average feed conversion ratio (FCR) will be calculated on approximate study days 14, 28, and 35 (i.e , days 0-14, 14-28, 0-28, 0-35, and 28-35) using the total feed consumption forthe pen divided by the total weight of the surviving birds, and as described elsewhere herein. Adjusted feed conversion ratios will be calculated using the total feed consumption in the pen divided by the total weight of surviving birds plus the weight of birds that died or were removed from a respective pen.
  • Eimeria inoculum mixtures will be administered in 1 ml volume by oral gavage on Day 14 to the birds in the infected treatments outlined above.
  • the challenge will include the following amounts of oocysts per treatment group: approximately 4,000 Eimeria maxima oocysts per bird, approximately 10,000 acervulina Eimeria oocysts per bird, and approximately 2,000 Eimeria tenella oocysts per bird in 1 ml volumes via oral gavage.
  • excreta will be collected from three birds per pen by squeezing the bird’s hind ends. Samples from all three birds will be collected individually and assayed for oocyst counts using the McMasters method or equivalent counting method. Oocysts per gram (OPG) of excreta will be recorded. On days 21 and 28 the three birds assayed for oocyst count will be assayed for ceca lesion presence using lesion scoring methods as discussed elsewhere herein. Morbidity and mortality will also be documented.
  • ppm parts per million
  • percentage percentage
  • ratios are on a by weight basis. Percentage on a by weight basis (% w/w) is also referred to as weight percent (wt.%) or percent by weight (% wt.) herein.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

La présente divulgation concerne des compositions d'additifs alimentaires et des méthodes de traitement et de prévention de la coinfection aux bactéries Clostridium et aux protozoaires Eimeria. Les compositions d'additifs alimentaires peuvent comprendre un produit de fermentation microbienne présent dans la composition d'additifs alimentaires en une quantité efficace pour produire un effet inhibiteur contre les bactéries Clostridium et les protozoaires Eimeria chez un animal. Les bactéries Clostridium peuvent comprendre Clostridium perfringens et les protozoaires Eimeria peuvent comprendre l'un quelconque parmi Eimeria acervulina,, Eimeria maxima ou Eimeria tenella. L'effet inhibiteur peut comprendre une inhibition directe ou indirecte de la croissance de bactéries Clostridium et une reproduction directe ou indirecte ou un délestage de protozoaires Eimeria. L'effet inhibiteur contre les bactéries Clostridium et les protozoaires Eimeria peut conduire à un ou plusieurs effets bénéfiques pour l'animal. D'autres aspects sont également inclus dans la description.
PCT/US2023/021898 2022-05-12 2023-05-11 Compositions et méthodes de traitement et de prévention d'une coinfection avec eimeria et clostridium WO2023220281A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263364587P 2022-05-12 2022-05-12
US63/364,587 2022-05-12

Publications (1)

Publication Number Publication Date
WO2023220281A1 true WO2023220281A1 (fr) 2023-11-16

Family

ID=86732219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/021898 WO2023220281A1 (fr) 2022-05-12 2023-05-11 Compositions et méthodes de traitement et de prévention d'une coinfection avec eimeria et clostridium

Country Status (1)

Country Link
WO (1) WO2023220281A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
US20200253240A1 (en) * 2015-10-27 2020-08-13 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US20200376015A1 (en) * 2017-07-25 2020-12-03 Dsm Ip Assets B.V. Use of sophorolipids as feed additive
US20210283198A1 (en) * 2020-03-12 2021-09-16 Life Rainbow Biotech Co., Ltd. Method for treating and/or preventing coccidiosis
US20220048958A1 (en) * 2020-08-12 2022-02-17 Zivo Bioscience, Inc. Use of variovorax microbes as an alternative treatment for coccidiosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
US20200253240A1 (en) * 2015-10-27 2020-08-13 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US20200376015A1 (en) * 2017-07-25 2020-12-03 Dsm Ip Assets B.V. Use of sophorolipids as feed additive
US20210283198A1 (en) * 2020-03-12 2021-09-16 Life Rainbow Biotech Co., Ltd. Method for treating and/or preventing coccidiosis
US20220048958A1 (en) * 2020-08-12 2022-02-17 Zivo Bioscience, Inc. Use of variovorax microbes as an alternative treatment for coccidiosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Commercial Poultry Nutrition", 2005, UNIVERSITY BOOKS
"Feeding Poultry: The Classic Guide to Poultry Nutrition for Chickens, Turkeys, Ducks, Geese, Gamebirds, and Pigeons", 2003, NORTON CREEK PRESS
ABBAS RAO Z ET AL: "Anticoccidial effects of acetic acid on performance and pathogenic parameters in broiler chickens challenged with Eimeria tenella", PESQUISA VETERINARIA BRASILEIRA, vol. 31, no. 2, February 2011 (2011-02-01), BR, pages 99 - 103, XP093068623, ISSN: 0100-736X *
TALUKDAR PRABHAT K. ET AL: "Inactivation Strategies for Clostridium perfringens Spores and Vegetative Cells", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 83, no. 1, 21 October 2016 (2016-10-21), US, XP093068598, ISSN: 0099-2240, DOI: 10.1128/AEM.02731-16 *

Similar Documents

Publication Publication Date Title
US11801272B2 (en) Bacillus strains improving health and performance of production animals
US20230372413A1 (en) Bacillus strains improving health and performance of production animals
JP6991162B2 (ja) プロバイオティック活性を示すバチルス・サブティリス（Ｂａｃｉｌｌｕｓ ｓｕｂｔｉｌｉｓ）菌株
US11291695B2 (en) Bacillus subtilis strains improving animal performance parameters
KR101370941B1 (ko) 신규 바실러스 서브틸리스
Latorre et al. Effects of the inclusion of a Bacillus direct-fed microbial on performance parameters, bone quality, recovered gut microflora, and intestinal morphology in broilers consuming a grower diet containing corn distillers dried grains with solubles
US11173184B2 (en) Bacillus subtilis strain with probiotic activity
PH12015501581B1 (en) Method for using a bacillus subtilis strain to enhance animal health
US20170042949A1 (en) System and method for production of shelf stable probiotics for animal nutrition enhancement
JP5998273B2 (ja) 新たなバチルス・サブチルス｛ｎｏｖｅｌｂａｃｉｌｌｕｓｓｕｂｔｉｌｉｓ｝
EP3203858A1 (fr) Souches de bacillus à germination rapide et à activité antimicrobienne contre clostridium perfringens
Józefiak et al. The dose response effects of liquid and lyophilized Carnobacterium divergens AS7 bacteriocin on the nutrient retention and performance of broiler chickens
WO2021144172A1 (fr) Souches de bacillus ayant la capacité de dégrader des composés azotés inorganiques
US11260084B2 (en) Feed additive formulation and methods of making and using the same
Ciurescu et al. Use of brewer’s yeast () in broiler feeds to replace corn gluten meal with or without probiotic additives
US20220168363A1 (en) Compositions containing bacillaene producing bacteria or preparations thereof
WO2023220281A1 (fr) Compositions et méthodes de traitement et de prévention d'une coinfection avec eimeria et clostridium
Hassanien et al. Physiological and haematological responses of the Nile tilapia (Oreochromis niloticus) fed on diets supplemented with probiotics
Gibbs et al. A probiotic and mixed-enzymes combination reduces the inflammatory response, faecal shedding and systemic spread of Campylobacter jejuni in broilers
WO2023220275A1 (fr) Compositions et méthodes de traitement et de prévention d'une infection par la coccidiose
WO2023220272A1 (fr) Compositions et méthodes de traitement et de prévention d'une maladie associée à clostridium
Abdel Moati et al. Effect of dietary supplementation of probiotics, enzymes and their combination on growth performance, meat yield, intestinal microbiota and plasma analysis of broiler chicks
RU2804144C2 (ru) Композиции, содержащие бактерии, продуцирующие бациллен, или его препараты
Dan et al. Autochthonous phytase-producing bacteria isolated from the gastrointestinal tracts of four Indian freshwater teleosts: characterization and identification
WO2023220279A1 (fr) Compositions et méthodes pour le traitement et la prévention d'une infection par campylobacter

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23729601

Country of ref document: EP

Kind code of ref document: A1